Johns Hopkins Tests Deliberate Pacing Trick to Rescue Failing Hearts
A pilot trial explores whether intentionally inducing brief daily dyssynchrony via pacemaker can retrain failing heart muscle in humans.
Summary
Heart failure affects millions, yet three-quarters of patients cannot benefit from cardiac resynchronization therapy because their hearts beat in sync already. Johns Hopkins researchers developed a novel pacemaker strategy called PITA — pacemaker induced transient dyssynchrony — that deliberately disrupts normal heart rhythm for several hours each night, then restores synchrony. The idea, borrowed from animal studies, is that briefly stressing the heart with dyssynchrony and then correcting it triggers beneficial molecular changes: better calcium handling, improved beta-receptor sensitivity, and stronger muscle contraction. This completed pilot trial tested whether the approach is feasible, safe, and tolerable in real dilated cardiomyopathy patients who already have implanted Medtronic devices. If results are promising, a larger human trial measuring actual heart function improvements is planned.
Detailed Summary
Heart failure remains one of the leading causes of death and hospitalization worldwide, affecting over 25 million people globally. While cardiac resynchronization therapy has proven effective for a subset of patients whose hearts beat out of sync, roughly 75 percent of heart failure patients have normal electrical coordination and are ineligible for this treatment. This unmet need has driven researchers at Johns Hopkins to explore an entirely new therapeutic concept.
The PITA strategy — pacemaker induced transient dyssynchrony — deliberately creates electrical dyssynchrony by pacing the right ventricle for approximately six hours each night, then restoring normal synchronous pacing for the remainder of the day. The hypothesis is that this oscillation between dyssynchrony and resynchronization repeatedly activates the same beneficial cellular pathways triggered by conventional CRT, even in patients who start with synchronous contraction.
Preclinical evidence from a canine dilated cardiomyopathy model was compelling. Animals receiving PITA showed reduced chamber dilation, improved contractile function, enhanced beta-adrenergic responsiveness, and better myofiber architecture compared to heart failure controls. These molecular and structural improvements suggested the concept was ready for first-in-human testing.
This completed pilot study leveraged pre-existing Medtronic pacemaker-defibrillators already implanted in dilated cardiomyopathy patients per standard clinical guidelines. The primary goal was not to measure efficacy but to confirm that the protocol is safe and that patients can tolerate the nightly dyssynchrony episodes without adverse events. Completion of this feasibility phase clears the path toward a larger, powered trial measuring left ventricular function outcomes.
If the PITA approach proves effective in humans, it could expand life-extending cardiac device therapy to the majority of heart failure patients currently left without an electrophysiological option — a major shift in how cardiologists manage this condition.
Key Findings
- PITA uses existing implanted pacemakers to induce nightly right ventricular dyssynchrony for ~6 hours, requiring no new hardware.
- Canine models showed PITA improved chamber size, contractile strength, and beta-adrenergic signaling versus untreated heart failure.
- 75% of heart failure patients are ineligible for conventional CRT, making PITA a potentially high-impact alternative strategy.
- This pilot trial (now completed) focused on feasibility, safety, and tolerability as prerequisites for a larger efficacy study.
- The approach targets dilated cardiomyopathy patients, a population with limited electrophysiological treatment options.
Methodology
Pilot feasibility trial (Phase N/A) conducted at Johns Hopkins University in dilated cardiomyopathy patients with pre-existing Medtronic pacemaker-defibrillators. The intervention programmed devices to deliver right ventricular pacing for 6 hours nightly (inducing dyssynchrony) followed by atrial synchronous pacing. Primary endpoints were safety and tolerability rather than functional efficacy.
Study Limitations
Summary is based on the abstract and ClinicalTrials.gov registration only; full results have not been reviewed. The trial was a small feasibility study not powered to detect changes in left ventricular function, so no efficacy conclusions can be drawn. Translation from canine dilated cardiomyopathy models to human outcomes is unproven and requires confirmation in larger randomized trials.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.